On Dec. 29, 2021, the Department of Defense (DOD), on behalf of and in coordination with the U.S. Department of Health and Human Services, awarded a $136.7 million contract to MilliporeSigma to establish nitrocellulose membrane production capacity in the United States.
Nitrocellulose membrane is a critical material used in manufacturing SARS-CoV-2 rapid point-of-care tests. This industrial base expansion effort will allow MilliporeSigma to establish a nitrocellulose manufacturing capability in its Sheboygan, Wisconsin facility to support more than 83.3 million tests per month for COVID-19 testing and future needs.
The DOD’s Defense Assisted Acquisition Cell (DA2) led this effort in coordination with the Department of the Air Force’s Acquisition COVID-19 Task Force (DAF ACT) supported by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) who facilitates the DA2’s Screening & Diagnostics industrial base expansion efforts. This effort was funded through the American Rescue Plan Act (ARPA) to support domestic industrial base expansion for critical medical resources.